Skip to Main Content

Latest News

Advertisement
Advertise Here
March 7, 2011
Volume 89, Number 10
p. 10

Daiichi Will Buy Plexxikon

Pharmaceuticals: Deal adds to spending spree by Japan’s drugmakers

Lisa M. Jarvis

  • Print this article
  • Email the editor

Latest News



October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

PLX4032 is shown bound to the BRAF protein. Proc. Natl. Acad. Sci. USA, DOI: 10.1073/pnas.0711741105
PLX4032 is shown bound to the BRAF protein.

Another Japanese pharmaceutical company is pursuing a major Western purchase. Daiichi Sankyo announced that it will pay $805 million up front for Plexxikon, a Berkeley, Calif.-based biotech firm.

Plexxikon could score an additional $130 million from the deal if its lead drug candidate, PLX4032, gains marketing approval.

PLX4032 has generated excitement as one of the most promising oncology candidates in the drug pipeline. The small molecule blocks a mutation BRAF, which occurs in about half of patients with melanoma, a form of skin cancer that has proven challenging to combat.

In January, Plexxikon reported early results from a Phase III clinical trial showing PLX4032 increased overall survival of melanoma patients with the BRAF mutation when compared with dacarbazine, the current standard of care. With Roche, its development partner for PLX4032 in the U.S. and Europe, Plexxikon expects to file for regulatory approval in those markets later this year.

In addition to PLX4032, Daiichi gains a Plexxikon compound that blocks three kinases and is expected to begin Phase II trials for the treatment of several cancers later this year. For Daiichi, the purchase adds to an oncology drug portfolio that has expanded in recent years through a marketing pact with Amgen and the purchase of Germany’s U3 Pharma.

The deal is the latest in a spate of licensing agreements and acquisitions by Japanese drug companies. In the past month, Kyowa Hakko Kirin agreed to pay $470 million for Scottish specialty pharma firm ProStrakan; Astellas Pharma forked over $125 million for Aveo Pharmaceuticals’ tivozanib, a cancer drug in Phase III trials; and Astellas agreed to pay $68 million for the European rights to Optimer Pharmaceuticals’ narrow-spectrum antibiotic fidaxomicin, which is under regulatory review in the U.S. and Europe.

The Japanese spending spree is driven by aging product portfolios, government price pressures, and a sudden influx of generic drug competition in Japan that has many firms scrambling to increase their presence abroad, says Michael Latwis, corporate analyst for Pharmaview, part of the health care consulting firm Decision Resources. The strength of the yen against the dollar has made U.S. assets particularly attractive, Latwis adds.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!